Introduction
============

Intracerebral hemorrhage (ICH) is a common cerebrovascular disease with a high mortality and poor outcomes in clinical practice, and also the leading cause of death and disability in elderly patients.[@b1-ndt-13-041] It was reported to account for about 10% of all strokes and 30% of all cerebrovascular diseases.[@b2-ndt-13-041],[@b3-ndt-13-041] The mortality rate could be up to 50%, and the mortality rate in one month could be up to 40%.[@b3-ndt-13-041],[@b4-ndt-13-041] Moreover, there could be up to 40% of severely disabled survivors.[@b3-ndt-13-041] Normally, the edema and hematoma expansion are the two major factors contributing to worsened outcomes and secondary damage.[@b5-ndt-13-041]

Many factors could lead to ICH, but hypertension is the major cause of ICH, and the hypertensive ICH (HICH) is a common neurological disease. To date, there are still no effective drug therapies for HICH.[@b6-ndt-13-041] Moreover, HICH is characterized by high incidence, high mortality and high morbidity, which seriously endangers the health of patients and causes substantial economic burden for families and society. Therefore, it is urgently necessary to develop an effective therapy for this disease.

During the treatment, the key point is to quickly clear the hematoma and reduce the intracranial pressure.[@b7-ndt-13-041] Along with minimally invasive technique, minimally invasive surgery (MIS) for HICH is gaining increasing attention. It could effectively decrease the mortality rate in the acute treatment of patients with HICH.[@b8-ndt-13-041] Additionally, some previous studies reported that the mild hypothermia therapy (MHT) could be useful for neuroprotection and be used to treat cerebral edema after acute brain injury.[@b9-ndt-13-041]--[@b11-ndt-13-041] Previous study reported that the addition of MHT could significantly improve the efficacy of MIS in treating HICH.[@b12-ndt-13-041] Therefore, the aim of this study was to review the available published studies and conduct a meta-analysis to systematically assess whether the combined application of MIS and local MHT (LMHT) (MIS+LMHT) could result in a better efficacy than MIS alone.

Methods
=======

Study selection
---------------

The first step of this meta-analysis was to obtain the eligible clinical trials. We conducted electronic searches in the following databases: Cochrane Controlled Trails Register, PubMed, Embase, Web of Science, Chinese Biomedical Literature Database on Disc and Chinese National Knowledge Infrastructure (dated up to September 2016). The search terms that we used were "hypothermia", "minimally invasive" and "hypertensive cerebral hemorrhage". No language restriction was set to avoid the potential language bias. Reference documents listed in the eligible studies and conference summaries were also reviewed. The inclusion criteria included the following items: 1) randomized clinical trials comparing the MIS+LMHT with MIS alone; 2) patients with hypertensive cerebral hemorrhage over 18 years of age; 3) the outcomes including at least one of these three indexes: response rate, mortality rate and neurologic function; and 4) patients could provide informed consent. The exclusion criteria included the following items: 1) no control group or not used MIS as the control group and 2) case reports, reviews and duplicate studies.

Outcome measures
----------------

Response rate and mortality rate were chosen as the primary outcomes. The response rate was defined according to the criteria of the included studies. The neurologic function, Barthel index and side effects were chosen as the secondary outcomes. The neurologic function was assessed according to the China Stroke Scale (CSS). The Barthel index was used to assess the activities of daily living (ADL) after treatment. Because pneumonia might be the main side effect caused by hypothermia,[@b13-ndt-13-041] we only analyzed the incidence of pneumonia to assess the acceptability of these treatment methods.

Data extraction
---------------

In order to ensure the high accuracy of the extracted data, two authors (Yu Han and Ke Sheng) were arranged to independently screen the potential studies according to the aforementioned inclusion/exclusion criteria and extract the data. Any disagreement was resolved by discussion. The extracted data included the demographic data of the patients, the parameters of the MIS and LMHT, the first author and outcomes (primary and secondary outcomes). Good-faith efforts were made to obtain the data which were not available from the included studies.

Statistical analysis
--------------------

RevMan 5.1 software was used to conduct the meta-analysis. For discontinuous data, the summary odds ratio (OR) was used as the effect size; for continuous data, the weighted mean difference (WMD) was used as the effect size. The chi-square test and *I*^2^ index were used to assess the heterogeneity.[@b14-ndt-13-041] If the corresponding *P*-value was more than 0.10 and *I*^2^ was less than 50%, then the Mantel--Haenszel fixed-effects model was used; otherwise, the random-effects model was used. The potential presence of publication bias was assessed using funnel plot. This meta-analysis was conducted according to the recommendations.[@b15-ndt-13-041]

Results
=======

Literature search
-----------------

At first, we obtained 157 potentially relevant random-ized clinical trials. Based on the inclusion and exclusion criteria, 129 studies were excluded. The reasons for exclusion included the following: 1) no randomization, 2) no control group, 3) compared the MIS+LMHT with the conservative treatment, 4) no available data, 5) did not use MIS and 6) being a retrospective study. Finally, 28 clinical trials composed of 2,325 adult patients with hypertensive cerebral hemorrhage were included in this meta-analysis.[@b16-ndt-13-041]--[@b43-ndt-13-041] The matched demographic data were observed in the included studies ([Table 1](#t1-ndt-13-041){ref-type="table"}). More than half of the included studies used cooling blanket as the device of LMHT. The detailed information of treatment methods is provided in [Table 2](#t2-ndt-13-041){ref-type="table"}.

Response rates
--------------

Response rate was available for 23 trials ([Figure 1](#f1-ndt-13-041){ref-type="fig"}). Overall, 916 of 1,156 (79.2%) patients receiving the MIS+LMHT and 673 of 1,129 (59.6%) patients receiving MIS alone were classified as responders. No heterogeneity (*I*^2^=0%, *P*=0.63) existed. Then, the fixed-effects model was used. The pooled OR was 2.68 with 95% confidence interval (CI)=2.22--3.24, which indicated that the MIS+LMHT could yield a higher response rate than MIS alone. The funnel plot showed that there was no publication bias ([Figure 2](#f2-ndt-13-041){ref-type="fig"}).

Mortality rates
---------------

Mortality rate was available for 18 trials ([Figure 3](#f3-ndt-13-041){ref-type="fig"}). Overall, 79 of 883 (8.9%) patients receiving the MIS+LMHT and 162 of 868 (18.7%) patients receiving MIS alone died after treatment. No heterogeneity (*I*^2^=0%, *P*=0.83) existed. Then, the fixed-effects model was used. The pooled OR was 0.43 with 95% CI=0.32--0.57, which indicated that the MIS+LMHT could yield a lower mortality rate than MIS alone. The funnel plot showed that there was no publication bias ([Figure 2](#f2-ndt-13-041){ref-type="fig"}).

Neurologic function
-------------------

Among the included studies, 11 studies used CSS to assess the neurologic function of patients ([Figure 4](#f4-ndt-13-041){ref-type="fig"}). Eight of 11 studies assessed the neurologic function one month after treatment; two studies conducted the assessment 21 days later and one study 14 days later. Heterogeneity (*I*^2^=91%, *P*\<0.0001) existed. Then, the random-effects model was used. The pooled WMD was −5.83 with 95% CI=−7.18 to −4.47, which indicated that the MIS+LMHT could be more effective than MIS alone in improving the neurologic function of patients. The funnel plot showed that there was no publication bias ([Figure 2](#f2-ndt-13-041){ref-type="fig"}).

Barthel index
-------------

Seven studies assessed ADL using Barthel index one month after treatment ([Figure 5A](#f5-ndt-13-041){ref-type="fig"}). Heterogeneity (*I*^2^=67%, *P*=0.006) existed. Then, the random-effects model was used. The pooled WMD was 8.17 with 95% CI=5.16--11.19. Ten studies assessed ADL three months after treatment ([Figure 5B](#f5-ndt-13-041){ref-type="fig"}). Heterogeneity (*I*^2^=87%, *P*\<0.00001) existed. Then, the random-effects model was used. The pooled WMD was 10.75 with 95% CI=6.77--14.73. No publication bias existed ([Figure 2](#f2-ndt-13-041){ref-type="fig"}). These results indicated that the MIS+LMHT could be more effective than MIS alone in improving the ADL of patients.

Side effects
------------

Only three studies assessed the side effects of the two treatment methods. Overall, 17 of 77 patients receiving the MIS+LMHT and 16 of 76 patients receiving the MIS alone experienced pneumonia. The pooled OR was 1.05 with 95% CI=0.43--2.59, which indicated that the incidence of pneumonia was similar between these two treatment methods.

Discussion
==========

We conducted this meta-analysis of 28 randomized clinical trials to compare the efficacy of MIS+LMHT with MIS alone in the treatment of patients with HICH. The results showed that the MIS+LMHT could yield higher response rate (OR=2.68) and lower mortality rate (OR=0.43). Moreover, this treatment modality could significantly improve the neurologic function and ADL of patients. With respect to the analysis of side effects, only three studies reported the number of patients with pneumonia, which was insufficient to make a robust conclusion on the safety of the MIS+LMHT. However, these results demonstrated that the LMHT could be an effective augmentation strategy for MIS in treating patients with HICH.

In this study, almost all relevant randomized clinical trials were included, but some trials might have been missed, partly because these were published in some journals that are not indexed by international databases. Fortunately, it is likely that these trials are of low quality, and could not significantly affect the results.[@b44-ndt-13-041] Additionally, there was one trial without the needed data,[@b45-ndt-13-041] and despite our best efforts, we could not obtain them. However, this trial concluded that the MIS+LMHT could be good at protecting nerve cell and promoting neurofunctional rehabilitation. Therefore, this trial would not affect our conclusion.

Under conditions of mild hypothermia, the oxygen consumption and metabolic rate in brain tissue are decreased, the production of free radicals is reduced and the synthesis of xanthine oxidase is slowed down and then the tissue damage could be alleviated. Meanwhile, the abnormal sodium--calcium exchange between cell membrane and sarcoplasmic reticulum is suppressed, which could alleviate the calcium overload.[@b46-ndt-13-041] Under normal conditions, vasoactive substances, such as endothelin and vascular vasopressin, are in dynamic equilibrium to maintain the systolic and diastolic function of blood vessels.[@b47-ndt-13-041] The acute period of ICH is usually accompanied by the disorder of vasoactive substances. The substantial production of endothelin and vascular vasopressin could further aggravate cerebral ischemia. Previous studies reported that the mild hypothermia could reduce the level of endothelin and vascular vasopressin.[@b40-ndt-13-041],[@b48-ndt-13-041]

Previous studies on ischemic and hemorrhagic stroke subtypes showed that the mild hypothermia (body temperature reduced by 3°C--5°C) was neuroprotective.[@b49-ndt-13-041],[@b50-ndt-13-041] But one point should be noticed in clinical practice: systemic mild hypothermia is difficult to perform because of its possible side effects.[@b10-ndt-13-041],[@b11-ndt-13-041] Alternatively, local mild hypothermia could quickly obtain the target temperature and overcome the potential side effects.[@b51-ndt-13-041] Therefore, compared to systemic mild hypothermia, the local mild hypothermia could be more effective in treating patients with HICH.

Limitations
===========

There were several limitations. First, all of the included studies were from the People's Republic of China, which might limit the applicability of our findings.[@b52-ndt-13-041] Second, only three studies were used to analyze the side effects; hence, future studies are needed to further assess the safety of the MIS+LMHT. Third, the target temperature and treatment time of LMHT were not consistent, but there were also the general problems for meta-studies to solve.[@b53-ndt-13-041],[@b54-ndt-13-041]

Conclusion
==========

By pooling analysis of 28 randomized clinical trials, we found that the addition of LMHT could significantly improve the efficacy of MIS in the treatment of patients with HICH. The OR of response rate and mortality rate was 2.68 and 0.43, respectively, which was in favor of the MIS+LMHT. The neurologic function and ADL were also found to be improved. The clinical applicability of this modality showed greater promise and should be further explored and optimized.
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###### 

Characteristics of patients in included studies

  Study                             N     Female/male   Mean age (SD) (years)   Mean OT (SD) (hours)   GCS        NF (MIS+HT vs MIS)
  --------------------------------- ----- ------------- ----------------------- ---------------------- ---------- ----------------------
  Chen[@b16-ndt-13-041]             96    29/67         56.3 (6.4)              NA                     NA         33.2 vs 31.5 (CSS)
  Chen[@b17-ndt-13-041]             89    34/55         56.15 (8.0)             NA                     5≤GCS      38.1 vs 36.8 (CSS)
  Wang[@b18-ndt-13-041]             60    23/37         52.7 (10.82)            6.96 (0.84)            GCS≤8      42.2 vs 42.1 (ESS)
  Yu et al[@b19-ndt-13-041]         112   53/59         59.80 (4.13)            NA                     NA         43.4 vs 42.4 (ESS)
  Peng and Zhou[@b20-ndt-13-041]    48    18/30         57.24 (11.24)           8.55 (2.14)            NA         35.0 vs 34.9 (CSS)
  Chen et al[@b21-ndt-13-041]       100   39/41         53.65 (10.12)           5.3 (0.8)              NA         35.1 vs 33.6 (CSS)
  Liu[@b22-ndt-13-041]              80    19/61         59.3 (3.5)              NA                     NA         NA
  Jia and Ding[@b23-ndt-13-041]     140   42/98         65.31 (6.75)            3.1 (0.59)             NA         28.5 vs 28.9 (CSS)
  Yang[@b24-ndt-13-041]             80    31/49         55.18 (10.84)           NA                     NA         18.8 vs 18.7 (NIHSS)
  Ou[@b25-ndt-13-041]               98    39/59         66.15 (7.6)             NA                     NA         36.8 vs 37.6 (CSS)
  Zhao et al[@b26-ndt-13-041]       98    34/62         65.09 (5.31)            NA                     NA         NA (CSS)
  He[@b27-ndt-13-041]               76    29/47         58.3 (17.5)             NA                     NA         NA (CSS)
  Shen[@b28-ndt-13-041]             80    43/37         56.65 (7.4)             NA                     3≤GCS≤12   38.4 vs 38.0 (CSS)
  Lin[@b29-ndt-13-041]              86    37/49         60.65 (10.67)           NA                     NA         NA
  Xu[@b30-ndt-13-041]               60    23/37         56.3 (1.6)              NA                     NA         NA
  Ye[@b31-ndt-13-041]               98    30/68         58.7 (9.6)              NA                     NA         48.9 vs 51.3 (ESS)
  Bei and Zhao[@b32-ndt-13-041]     48    22/26         53.2 (6.5)              NA                     NA         27.9 vs 28.1 (CSS)
  Zhang and Xie[@b33-ndt-13-041]    120   43/77         55.28 (11.24)           6.87 (0.37)            GCS≤8      33.5 vs 32.7 (CSS)
  Xie[@b34-ndt-13-041]              80    34/46         56.4 (6.4)              NA                     3,GCS≤8    44.3 vs 43.4 (ESS)
  Zhang[@b35-ndt-13-041]            51    19/32         57.7 (5.6)              NA                     GCS≤8      38.6 vs 36.0 (CSS)
  Zhou and Chen[@b36-ndt-13-041]    40    18/22         57.2 (11.2)             8.56 (2.14)            NA         35.0 vs 34.9 (CSS)
  Ning et al[@b37-ndt-13-041]       304   132/172       64.1 (7.54)             NA                     3,GCS≤8    34.1 vs 33.5 (CSS)
  Bai[@b38-ndt-13-041]              86    36/50         50.03 (10.31)           NA                     GCS≤8      NA
  Chen et al[@b39-ndt-13-041]       134   51/83         57.48 (18.75)           7.09 (8.05)            GCS≤8      NA (CSS)
  Zhang and Feng[@b40-ndt-13-041]   152   55/97         65.44 (4.38)            3.16 (0.57)            GCS≤8      27.6 vs 28.5 (CSS)
  Yao[@b41-ndt-13-041]              79    35/44         73.7 (6.83)             NA                     5≤GCS≤8    13.8 vs 13.6 (NIHSS)
  Zuo[@b42-ndt-13-041]              53    19/34         66.7 (NA)               NA                     GCS≤8      NA
  Yang et al[@b43-ndt-13-041]       89    35/54         64.09 (7.62)            NA                     NA         34.1 vs 33.5 (CSS)

**Abbreviations:** SD, standard deviation; OT, onset time; GCS, Glasgow Coma Scale; NF, neurologic function; MIS, minimally invasive surgery; HT, hypothermia therapy; NA, not available; CSS, China Stroke Scale; ESS, European Stroke Scale; NIHSS, National Institutes of Health Stroke Scale.

###### 

Characteristic of included controlled trials

  Study                             MIS   HT     Random                      
  --------------------------------- ----- ------ ----------- -------- ------ -----
  Chen[@b16-ndt-13-041]             Yes   YL-1   YZK-1086    32--35   3--5   Yes
  Chen[@b17-ndt-13-041]             Yes   YL-1   Ice hat     33--35   3--5   Yes
  Wang[@b18-ndt-13-041]             Yes   YL-1   HGT-200Ô    33--34   3--5   Yes
  Yu et al[@b19-ndt-13-041]         Yes   YL-1   HGT-200II   33--34   2--7   Yes
  Peng and Zhou[@b20-ndt-13-041]    Yes   NA     CB          33--35   3--5   Yes
  Chen et al[@b21-ndt-13-041]       Yes   NA     CB          33--35   3--5   Yes
  Liu[@b22-ndt-13-041]              Yes   NA     CB          32--35   3--5   Yes
  Jia and Ding[@b23-ndt-13-041]     Yes   YL-1   YZK-1066    33--35   2--3   Yes
  Yang[@b24-ndt-13-041]             Yes   YL-1   CB          33--35   3--5   Yes
  Ou[@b25-ndt-13-041]               Yes   YL-1   YZK-1086    32--35   NA     Yes
  Zhao et al[@b26-ndt-13-041]       Yes   NA     CB          33--35   3--7   Yes
  He[@b27-ndt-13-041]               Yes   YL-1   HDB-01      33--35   3--5   Yes
  Shen[@b28-ndt-13-041]             Yes   NA     CB          32--35   2--5   Yes
  Lin[@b29-ndt-13-041]              Yes   NA     CB          33--35   2--5   Yes
  Xu[@b30-ndt-13-041]               Yes   NA     CB          33--35   2--5   Yes
  Ye[@b31-ndt-13-041]               Yes   YL-1   CB          33--35   2--5   Yes
  Bei and Zhao[@b32-ndt-13-041]     Yes   YL-1   CB          33--35   3--5   Yes
  Zhang and Xie[@b33-ndt-13-041]    Yes   YL-1   HGT-200Ô    33--34   3--5   Yes
  Xie[@b34-ndt-13-041]              Yes   YL-1   CB          33--35   3--5   Yes
  Zhang[@b35-ndt-13-041]            Yes   NA     NA          32--35   NA     Yes
  Zhou and Chen[@b36-ndt-13-041]    Yes   YL-1   CB          33--35   3--5   Yes
  Ning et al[@b37-ndt-13-041]       Yes   YL-1   CB          33--35   3--5   Yes
  Bai[@b38-ndt-13-041]              Yes   YL-1   CB          33--35   2--5   Yes
  Chen et al[@b39-ndt-13-041]       Yes   YL-1   CB          33--35   3--5   Yes
  Zhang and Feng[@b40-ndt-13-041]   Yes   YL-1   YZK-1066    33--35   NA     Yes
  Yao[@b41-ndt-13-041]              Yes   YL-1   CB          33--35   3--5   Yes
  Zuo[@b42-ndt-13-041]              Yes   YL-1   CB          33--35   3--7   Yes
  Yang et al[@b43-ndt-13-041]       Yes   YL-1   ICE-I       33--35   2--5   Yes

**Abbreviations:** MIS, minimally invasive surgery; HT, hypothermia therapy; CT, computed tomography; BT, body temperature; NA, not available; CB, cooling blanket.
